Insider Trading Activity Observed in Cytokinetics, Incorporated (NASDAQ:CYTK)

Core Insights - Cytokinetics, Incorporated is focused on developing innovative treatments for serious diseases, particularly heart failure and ALS, competing against major players like Amgen and Biogen [1] Insider Trading Activity - On January 5, 2026, Executive Vice President Andrew Callos sold 15,000 shares of CYTK at $60.28 each, reducing his total holdings to 50,440 shares [2] - In December 2025, Callos sold 1,042 shares at $65.96 on December 8 and 52,486 shares at $65.95 on December 5, totaling approximately $3.46 million in sales [2] Market Performance - The current market price of CYTK is $61.26, reflecting a slight decrease of 0.76% or $0.47 [3] - The stock has shown volatility, with a yearly high of $70.98 and a low of $29.31 [3] - Cytokinetics has a market capitalization of approximately $7.29 billion and a trading volume of 2,252,943 shares [3]